|[January 24, 2014]
ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2014 Financial Results
WALTHAM, Mass. --(Business Wire)--
Inc. (Nasdaq: IMGN), a biotechnology
company that develops novel anticancer therapeutics using its
antibody-drug conjugate (ADC (News - Alert)) technology, today announced that the
Company will host a conference call at 8:00 a.m. ET on Friday, January
31, 2014, to discuss ImmunoGen's financial results for the three-month
period ended December 31, 2013. Management also will provide an update
on the Company.
To access the live call by phone, dial 913-312-0388; the passcode is
8088204. The call also may be accessed through the Investor nformation
section of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available at
the same location through February 14, 2014.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
ADC technology uses a tumor-targeting engineered antibody to deliver one
of ImmunoGen's highly potent cancer-cell killing agents specifically to
tumor cells; the Company has also developed antibodies with anticancer
activity of their own. The most advanced compound with ImmunoGen's ADC
technology is Roche's Kadcyla®, which is marketed in the US
by Genentech and is also gaining approvals internationally. Additional
compounds are in clinical testing by ImmunoGen and through the Company's
partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More
information about ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, Inc., a
member of the Roche Group.
[ Back To TMCnet.com's Homepage ]